Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases.
about
Ocular melanoma: an overview of the current status.Management of conjunctival malignant melanoma: a review and update.Sinonasal melanoma arising from conjunctival primary acquired melanosis.Conjunctival melanoma: a review of conceptual and treatment advances.Histologic features of conjunctival melanoma predictive of metastasis and death (an American Ophthalmological thesis).TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.Melanocytic Nevus of the Tarsal ConjunctivaProspective study of sentinel lymph node biopsy for conjunctival melanoma.Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist.BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions.Tumors of the ocular surface: A review.Advances in the management of conjunctival melanoma.Evaluation of a short-term topical interferon α-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia.Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma.Focus on cutaneous and uveal melanoma specificities.Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.Expression of Multidrug Resistance Transporter ABCB5 in a Murine Model of Human Conjunctival Melanoma.Management of Conjunctival Melanoma: Critical Assessment of Sentinel Lymph Node Biopsy.Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey.PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.The use of strontium-90 Beta radiotherapy as adjuvant treatment for conjunctival melanoma.Sentinel lymph node biopsy for conjunctival malignant melanoma: surgical techniquesConjunctival keratoacanthoma.Systemic Treatment of Metastatic Conjunctival Melanoma.Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis.Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions.TERT promoter mutation is uncommon in acral lentiginous melanoma.[Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma].Amniotic Membrane Transplantation in Surgical Treatment of Conjunctival Melanoma: Long-term Results.When narrative medicine helps in the diagnosis of conjunctival melanoma – an exceptional case report.Updates in Ocular Surface Tumor Diagnostics.Conjunctival Metastasis of a Cutaneous MelanomaComparison of posterior lamellar resection versus lumpectomy for initial management of localized tarsal conjunctival sebaceous carcinoma in 54 cases
P2860
Q34653896-A84FA7E4-D24E-46D4-9350-FA20A5098D39Q34667481-7D14C815-6696-4470-AEB6-84676D762D52Q35109092-5ED8A97F-D15D-4707-97DD-0C4CC6CB6407Q36696509-0027A359-E32B-40AB-8D09-2F240059EE4BQ36898928-E3D02638-4615-4C3C-95F2-F50DC2C31FF5Q37040678-D58E478E-E84A-4993-AB1E-90269A1CCDB0Q37211471-C352FC0D-3CDF-47EC-ACEE-0E8B1E2DDDF3Q37345852-66E63321-4057-46CA-B10B-FBDA1D6B43B7Q38201794-D8B58E58-A7D5-4023-AFB9-856E9DBF94CDQ38381486-530ECA47-F840-4B19-94C9-329415494EE1Q38477793-DE622897-1546-4CC8-B28E-D77C1AB8CBFBQ38870401-505FBB61-3457-432E-8358-6BD7B2B09514Q38935282-11B3813B-628D-4F2D-89B6-2BD365E8D0B0Q39030720-971F1177-16DF-449A-9343-650A186F0988Q39312161-41E7ACFD-190C-492F-9262-3C0381825290Q39756781-67661F07-B5E8-4DFB-B3F0-29ACA415F681Q40399058-857090FE-FA3A-46F4-A570-C988F278DA3AQ40709215-0503AE02-D327-43A4-BB67-81E12A924573Q40838309-A5BF6579-F626-4E4A-BBF4-F1F1AA6CCF98Q41550899-A65150DF-7C91-46F3-9AA9-D5982E8EE7A9Q41874799-2E4604C4-4527-49BB-A256-89EEF56D5197Q42133440-0A3F524A-485E-4945-9BB8-DB5B2C4633BAQ46349143-224C7120-FD54-4199-B1CA-349BD38F02FFQ47108077-88A52F82-D7E9-4FBB-A21F-C66107061AECQ47566410-63F894E5-820E-4FCB-98B5-5154F85DA540Q47966722-772A7D84-FE74-4DE4-8F3C-AF690C24E9C7Q50931406-46BB0850-7109-43A9-A13D-A1C0C232A4D8Q54220234-18314444-782D-4B68-A2F2-1DB27C1D2998Q54238016-A6BA8BBF-6C68-4D8E-A140-C642653AB992Q55075201-00FB9295-F944-48C1-8BE3-EF7946E4CBB6Q55155216-A0D06057-1817-46E2-AB44-281D35C642A6Q55544558-89B15FEB-4EB7-4353-83A9-96C68502F000Q57494867-841266B2-EF32-48D9-82C1-02892C977017Q58777231-101818C5-2DDF-4B54-A24E-E8D83DF3AE23
P2860
Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases.
@en
Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases.
@nl
type
label
Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases.
@en
Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases.
@nl
prefLabel
Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases.
@en
Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases.
@nl
P2093
P1433
P1476
Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases
@en
P2093
Carol L Shields
Irina Belinsky
Jeremy S Markowitz
Jerry A Shields
Nina S George
Sara E Lally
P304
389-95.e1-2
P356
10.1016/J.OPHTHA.2010.06.021
P577
2010-08-17T00:00:00Z